Instil Bio Inc. (TIL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Instil Bio Inc. (TIL) has a cash flow conversion efficiency ratio of -0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.34 Million) by net assets ($110.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Instil Bio Inc. to measure how many days the company can operate on defensive assets alone.
Instil Bio Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Instil Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Instil Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Instil Bio Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen SEG Co Ltd
SHE:200058
|
0.108x |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
-0.001x |
|
Oneflow AB
ST:ONEF
|
-0.023x |
|
Theralase Technologies Inc.
V:TLT
|
-0.125x |
|
China Bicycle Co Holdings Ltd
SHE:200017
|
-0.043x |
|
CoAsia Corporation
KQ:045970
|
0.073x |
|
Euro Sun Mining Inc
TO:ESM
|
0.204x |
|
Daily Polymer
TWO:4716
|
0.039x |
Annual Cash Flow Conversion Efficiency for Instil Bio Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Instil Bio Inc. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Instil Bio Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $113.87 Million | $-36.62 Million | -0.322x | +2.17% |
| 2024-12-31 | $169.44 Million | $-55.70 Million | -0.329x | +9.50% |
| 2023-12-31 | $225.83 Million | $-82.03 Million | -0.363x | +26.69% |
| 2022-12-31 | $363.61 Million | $-180.16 Million | -0.495x | -125.24% |
| 2021-12-31 | $555.20 Million | $-122.14 Million | -0.220x | -117.17% |
| 2020-12-31 | $292.37 Million | $-29.62 Million | -0.101x | +84.58% |
| 2019-12-31 | $8.06 Million | $-5.29 Million | -0.657x | -- |
About Instil Bio Inc.
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.